Krzysztof Składowski was dismissed by Health Minister Izabela Leszczyna on March 26. She thanked him for his cooperation and "professional and committed performance of the extremely difficult tasks entrusted to him."
The new director, Slawomir Blamek, MD, PhD, is a professor at NIO-PIB, an independent researcher at the Department of Radiotherapy of the National Cancer Institute in Gliwice.
According to NIO-PIB in Gliwice:
Dr. Slawomir Blamek is a specialist in radiation oncology, author and co-author of many scientific articles published in Polish and foreign scientific journals, author of radiation treatment protocols used in clinical practice, and reviewer of scientific papers in Polish and foreign scientific journals (among others.Among others in the New England Journal of Medicine, Neurosurgery, Neuroradiology, Neurosurgical Review, Child's Nervous System, Radiation Oncology, Radiology and Oncology, Diabetes Research and Clinical Practice, European Journal of Paediatric Neurology, Frontiers in Oncology).
He is a member of many Polish and foreign scientific societies, including the International Brain Research Organization (IBRO), the Polish Society of Radiation Oncology (PTRO), the Polish Lymphoma Research Group (PGBCh), the Society of Innovative Health Technologies, the International Lymphoma Radiation Oncology Group (ILROG) and the Polish Association for Artificial Intelligence in Medicine.
The new director of the NIO-PIB in Gliwice graduated from the Faculty of Medicine with the Faculty of Medicine and Dentistry in Zabrze of the Silesian Medical University (then the Silesian Medical Academy) in Katowice with top grades and received his medical degree with honors in 2001. Since the beginning of his career, he has worked extensively in research and in 2008 received his doctorate in medical science on the basis of his dissertation "Evaluation of the results of treatment of cerebral arteriovenous hemangiomas by stereotactic radiosurgery." In the same year, he also received a specialist degree in radiation oncology. In January 2015, he was awarded the degree of Doctor of Medical Sciences by the Maria Sklodowska Curie Oncology Center - Institute in Warsaw. In 2023, with a very good result, he completed his MBA (Health Protection profile) at the Silesian University of Technology in Gliwice (the partner university in the MBA program of the Silesian University of Technology is Nyenrode Business Universiteit in the Netherlands).
Prof. Slawomir Blamek's numerous scientific interests include the effectiveness and tolerability of radiotherapy and stereotactic radiosurgery of brain tumors and non-cancerous lesions of the central nervous system, stereotactic extracranial radiosurgery, modern radiotherapy techniques, technical and physical aspects of stereotactic radiosurgery, genetics and epigenetics of tumors, intraoperative radiotherapy, radiotherapy of metastases and risk factors for their formation.
In recent years, he has been involved in research at the interface of cardiology and oncology, including studies of the ionizing radiation sensitivity of cardiac implantable devices, co-authoring national recommendations for the management of patients after implantation of such devices in radiotherapy. He is also researching the use of stereotactic radiotherapy in the treatment of patients with ventricular tachycardias resistant to other treatments. He is the principal investigator in the now-completed SMART-VT trial and the ongoing SMARTR-VT trial for the treatment of ventricular tachycardias. He is also a working group leader in the international STOPSTORM consortium that maintains a registry of patients undergoing radiotherapy for ventricular tachycardias.
As part of his interests involving innovative treatment techniques, he initiated a study with the acronym INTROSPECTION to explore the possibility of combining an advanced radiotherapy technique - radiotherapy with spatial dose differentiation - with immunotherapy in patients with advanced cancers and using innovative diagnostic methods - immuno-PET and proteomic studies - to evaluate the effect of this combination.
